Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zactima versus placebo in advanced or metastatic papillary or follicular thyroid carcinoma
2007-001890-27Phase 2Active
- Sponsor
- AstraZeneca
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in papillary thyroid cancer (PTC), follicular carcinoma (FTC) and well-differentiated thyroid cancer (WDTC) comparing Zactima with Placebo (2 arms). Primary endpoint: Progression-free survival. Started May 2007; status: active.
02
Drugs
vandetanib
03
Conditions
papillary thyroid cancer (PTC)follicular carcinoma (FTC)well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2007-001890-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001890-27.